Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128) - Top-Institutions - MDSpire

Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)

  • By

  • Fabien Moinard-Butot

  • Jonathan Thouvenin

  • Pierre Bigot

  • Nieves Martinez-Chanza

  • Victor Gaillard

  • Roberto Luigi Cazzato

  • Romain Boissier

  • Gaëlle Margue

  • Philippe Boudier

  • Denis Maillet

  • Marine Gross-Goupil

  • Jean-Christophe Bernhard

  • Philippe Barthélémy

  • January 10, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Immunotherapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Immunotherapy

  • #4

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, Île-de-France

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Immunotherapy

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Immunotherapy

Original Source(s)

Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)

  • by Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, Nieves Martinez-Chanza, Victor Gaillard, Roberto Luigi Cazzato, Romain Boissier, Gaëlle Margue, Philippe Boudier, Denis Maillet, Marine Gross-Goupil, Jean-Christophe Bernhard, Philippe Barthélémy

  • January 10, 2025

Related Content

Bioinformatics Investigations Uncover the Involvement of RIPK1 in Clear Cell Renal Cell Carcinoma

Kidney Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.

  • March 3, 2025

  • 1 min
Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis